Objective:

To explore recent breakthroughs in cell and gene therapy (CGT) and assess the maturity of the field.

Approach:

• Event Coverage: Filmed at ARM’s Meeting on the Med 2026 in Rome, featuring discussions with industry leaders.

Key Findings:

• Gene therapies are continuing to demonstrate their potential across a broader range of diseases.
• Regeneron's approval for inherited deafness marks an important milestone for the sector.
• Clinical value is extending beyond oncology into sensory disorders, rare diseases, and other areas of high unmet need.
• Industry leaders discussed innovative regulatory pathways, new reimbursement models, commercialization challenges, and long-term sustainability.

Interpretation:

The field of cell and gene therapy is evolving, with increasing clarity on clinical value and ongoing challenges.

Limitations:

• The discussion does not provide specific data or metrics on therapy effectiveness.
• Challenges in commercialization and long-term sustainability are acknowledged but not detailed.

Conclusion:

The conversation highlights progress and hurdles in making transformative therapies accessible to more patients.

Sources:

• IBTV